Return on Equity (ROE) Summary
NextCure's ROE measures the return generated on shareholders' equity:
- Annual: -85.00%
- Quarterly: -17.72%
- TTM: -68.38%
What is Return on Equity (ROE)?
Return on Equity measures a company's ability to generate profits from its shareholders' equity. It indicates how effectively the management is using the company’s assets to create profits. A higher ROE generally reflects well on the company’s management and its ability to generate profits without needing as much capital.
Related Metrics
Other important metrics to assess NextCure's profitability include:
- ROIC (Return on Invested Capital) - measures how effectively the company uses its invested capital to generate profits:
- Annual: -83.81%
- Quarterly: -17.28%
- TTM: -80.64%
- ROA (Return on Assets) - measures the return generated on the company's assets:
- Annual: -68.83%
- Quarterly: -14.35%
- TTM: -68.83%
- Profit Margin - indicates the profitability of the company relative to its revenue:
- Annual: 0.00%
- Quarterly: 0.00%
- TTM: 0.00%
These metrics provide insights into NextCure's profitability and efficiency in using its capital and assets to generate returns. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.
Annual ROE
-85.00%
Quarterly ROE
-17.72%
TTM ROE
-68.38%
NextCure Historical ROE
Historical ROIC
Historical ROA
NextCure Historical Profitability Metrics
The table below shows various profitability metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | ROE | ROIC | ROA | Profit Margin |
|---|---|---|---|---|
| 2024 | -85.00% | -83.81% | -68.83% | 0.00% |
| 2023 | -54.82% | -55.53% | -48.99% | 0.00% |
| 2022 | -41.45% | -40.17% | -37.70% | 0.00% |
| 2021 | -29.73% | -33.02% | -28.63% | 0.00% |
| 2020 | -11.30% | -12.54% | -10.82% | -148.32% |
| 2019 | -10.49% | -11.75% | -9.47% | -531.54% |
| 2018 | 48.57% | -17.12% | -15.44% | 0.00% |
| 2017 | 63.37% | -92.30% | -79.46% | 0.00% |
Related Metrics
Explore detailed financial metrics and analysis for NXTC.